1%

Question 1 of 30

Clinical symptoms in Marfan Syndrome (MFS) mostly involve three systems: cardiac, ophthalmologic, and skeletal. The treatment that is slowing the aortic dilatation and may prevent aortic dissection is

Rationale:
Losartan is the treatment that is slowing the aortic dilatation and may prevent aortic dissection. Losartan, an angiotensin receptor blocker (ARB), has shown significant promise in slowing aortic root dilatation in Marfan Syndrome by modulating TGF-β signaling, which is dysregulated in MFS. This mechanism directly addresses the connective tissue weakness contributing to aortic expansion and dissection risk. Clinical trials support its efficacy in stabilizing aortic diameter, thereby potentially preventing life-threatening complications. B: atenolol Atenolol, a beta-blocker, reduces hemodynamic stress on the aorta by lowering heart rate and blood pressure, but it does not directly modulate the underlying TGF-β pathway involved in MFS connective tissue pathology like ARBs do. C: enaloprile Enaloprile is an ACE inhibitor, which primarily reduces blood pressure by preventing angiotensin II formation. While beneficial for hypertension, ACE inhibitors do not specifically target the TGF-β dysregulation responsible for aortic dilatation in Marfan Syndrome. D: lisinoprile Lisinoprile, another ACE inhibitor, lowers systemic vascular resistance and blood pressure. Its mechanism does not address the fundamental connective tissue defects or the TGF-β signaling pathway crucial for mitigating progressive aortic root dilatation in Marfan Syndrome patients.